Blueprint Medicines Corp
NASDAQ:BPMC
Blueprint Medicines Corp
NASDAQ:BPMC
Price:
129.46
USD
0.14%
Market Closed
Market Cap:
$8.4B
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Blueprint Medicines Corp
NASDAQ:BPMC
|
US |
|
M
|
Malaysian Pacific Industries Bhd
KLSE:MPI
|
MY |
|
Amara Holdings Ltd
SGX:A34
|
SG |
|
Sprott Inc
TSX:SII
|
CA |
|
A
|
ATI Physical Therapy Inc
NYSE:ATIP
|
US |
|
C
|
Continental Resources Inc
F:C5L
|
US |
|
Silver X Mining Corp
XTSX:AGX
|
CA |
|
First Robinson Financial Cororation
OTC:FRFC
|
US |
|
S
|
Shalag Industries Ltd
TASE:SALG
|
IL |
|
Andersons Inc
NASDAQ:ANDE
|
US |
|
Acrow Formwork and Construction Services Ltd
ASX:ACF
|
AU |
|
F
|
FlexQube AB (publ)
STO:FLEXQ
|
SE |
|
H
|
HUTCHMED (China) Ltd
HKEX:13
|
HK |
|
G
|
Grand Baoxin Auto Group Ltd
HKEX:1293
|
CN |
|
J
|
J-Long Group Ltd
NASDAQ:JL
|
HK |
|
W
|
WeRide Inc
NASDAQ:WRD
|
CN |
|
B
|
Big Cheese Studio SA
WSE:BCS
|
PL |
Multiples-Based Value
The Multiples-Based Value of one
BPMC
stock under the Base Case scenario is
hidden
USD.
Compared to the current market price of 129.46 USD,
Blueprint Medicines Corp
is
hidden
.
Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
BPMC Multiples-Based Value
LOCKED
Multiples Across Competitors
BPMC Competitors Multiples
Blueprint Medicines Corp Competitors
Blueprint Medicines Corp Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
Blueprint Medicines Corp
NASDAQ:BPMC
|
8.4B USD | 14.9 | -53.7 | -51.3 | -46.6 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 690 872.8 | -160 127.7 | -194 446.1 | -192 227.3 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
370.2B USD | 6.1 | 88.4 | 14.7 | 20.4 | |
| US |
|
Exact Sciences Corp
NASDAQ:EXAS
|
355.4B USD | 109.4 | -1 708.3 | 15 870 | -1 791.9 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
188B USD | 5.1 | 24.4 | 14.1 | 14.1 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
166.6B USD | 5.7 | 19.6 | 12.3 | 15.1 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
110B USD | 9.2 | 27.8 | 20.9 | 21.8 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 091 | -533.6 | -581 | -565.5 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
78B USD | 5.4 | 17.3 | 12.7 | 14.5 | |
| AU |
|
CSL Ltd
ASX:CSL
|
69B AUD | 3.2 | 35.1 | 11.5 | 14.5 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.1 | -61.8 | -66.6 | -60.1 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
